The U.S. new cases 7-day rolling average are 12.4 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 4.3 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 65,471
U.S. Coronavirus deaths are at 901
U.S. Coronavirus immunizations have been administered to 64.6 % of the population
The 7-day rolling average rate of growth of the pandemic shows new cases improved and deaths worsened
CDC advisers recommend resuming use of Johnson & Johnson coronavirus vaccine
New Study Shows Long Haul COVID-19 Can Kill Patients Months After Infection
email article
So far in the pandemic, support for research on drug repurposing particularly for inexpensive generics has not played a huge role in finding new treatments for COVID-19, but that appears to be changing.
Critics charge that drug repurposing is like looking for a needle in a haystack. It does not always work, and can raise false hopes and waste resources. In a March 7 interview with
60 Minutes, for instance, NIH director Francis Collins, MD, PhD, said drug repurposing is only going to work if you re kind of lucky, because you re basically picking things that were developed for a different disease.
Boston University Social Innovation on Drug Resistance Program
Advocate Member
Drug resistance is an inevitable biological process driven by evolution, but made worse by human behavior, threatening to usher in a post-antibiotic era. While the new products created from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator s (CARB-X) preclinical product development support are an important step in preventing that; an equally important challenge is to understand the impact of human behavior on the evolution of drug-resistant microbes. The tools for this effort will be interdisciplinary, rooted in the social sciences.
To advance these important goals, the Institute for Health System Innovation & Policy and CARB-X created the Social Innovation on Drug Resistance (SIDR) Program, an interdisciplinary postdoctoral fellowship program focused on the interaction of human behavior and drug-resistant infections.